ZJYL revenueFY2025$20.69M
- FY YoY
- -12.0%
ZJYL revenue was $20.69M for fiscal 2025 (ended Sep 30, 2025), down 12.0% from fiscal 2024. It rose in 2 of the last 4 fiscal years.
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) financials
For fiscal 2025 (ended Sep 30, 2025), JIN MEDICAL INTERNATIONAL LTD. reported $20.69M of revenue and $1.19M of net income.
- Revenue, FY2025
- $20.69M
- Revenue growth, YoY
- -12.0%
- Net income, FY2025
- $1.19M
- Net income growth, YoY
- -67.6%
- Net margin
- 5.8%
- Free cash flow, FY2025
- -$3.73M
- EPS, diluted, FY2025
- $0.01
- EPS growth, YoY
- -50.0%
- Cash
- $7.46M
- P/E
- 559.05
- P/S
- 32.19
- Market cap
- $666.0M
FY2021FY2025
FY2021FY2025
FY2021FY2025
ZJYL revenue and earnings growth
ZJYL net incomeFY2025$1.19M
- FY YoY
- -67.6%
ZJYL net income was $1.19M for fiscal 2025 (ended Sep 30, 2025), down 67.6% from fiscal 2024. It rose in 3 of the last 4 fiscal years.
ZJYL EPSFY2025$0.01
- FY YoY
- -50.0%
ZJYL diluted EPS was $0.01 for fiscal 2025 (ended Sep 30, 2025), down 50.0% from fiscal 2024.
ZJYL free cash flowFY2025-$3.73M
ZJYL free cash flow was -$3.73M for fiscal 2025 (ended Sep 30, 2025), compared with -$1.35M in fiscal 2024.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $20.69M | $23.50M | $19.82M | $19.19M | $20.76M |
| Cost of revenue | $14.64M | $14.00M | $13.04M | $12.99M | $14.40M |
| Gross profit | $6.04M | $9.50M | $6.78M | $6.20M | $6.36M |
| Research and development | $1.56M | $1.50M | $1.54M | $1.89M | $1.57M |
| Selling, general and admin | $2.53M | $3.26M | $1.92M | $1.77M | $1.67M |
| Operating income | $608.2K | $3.64M | $2.87M | $2.13M | $2.63M |
| Pre-tax income | $1.60M | $4.18M | $3.22M | $2.74M | $2.88M |
| Income tax | $214.6K | $763.9K | $343.7K | $36.1K | $248.6K |
| Net income | $1.19M | $3.68M | $2.88M | $2.71M | $2.63M |
| EPS, basic | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 |
| EPS, diluted | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 |
| Diluted shares | 156.5M | 156.5M | 145.1M | 135.0M | 135.0M |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $7.46M | $8.14M | $6.93M | $4.79M | $3.67M |
| Short-term investments | $22.17M | $18.62M | $9.77M | $2.28M | - |
| Receivables | $5.81M | $5.91M | $3.28M | $3.83M | - |
| Inventory | $4.92M | $5.17M | $5.05M | $6.72M | - |
| Current assets | $44.14M | $42.82M | $31.12M | $18.90M | - |
| Total assets | $53.37M | $45.80M | $32.90M | $20.94M | - |
| Current liabilities | $23.80M | $17.15M | $8.92M | $5.70M | - |
| Short-term debt | $18.84M | $11.32M | $4.11M | - | - |
| Total liabilities | $23.80M | $17.25M | $8.92M | $5.70M | - |
| Shareholders' equity | $29.64M | $28.82M | $23.98M | $15.24M | $14.03M |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $2.90M | -$1.21M | $3.11M | $1.58M | $5.84M |
| Capital expenditures | $6.63M | $144.9K | $113.9K | $40.2K | $42.9K |
| Free cash flow | -$3.73M | -$1.35M | $2.99M | $1.54M | $5.80M |
| Investing cash flow | -$10.79M | -$9.51M | -$7.73M | -$120.9K | -$1.07M |
| Financing cash flow | $7.35M | $11.65M | $6.91M | $121.9K | -$2.87M |
| Depreciation and amortization | $243.4K | $237.8K | $225.9K | $362.6K | $346.6K |
Key ratios
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue growth, YoY | -12.0% | 18.6% | 3.3% | -7.6% | - |
| Net income growth, YoY | -67.6% | 27.7% | 6.3% | 2.8% | - |
| EPS growth, YoY | -50.0% | 0.0% | 0.0% | 0.0% | - |
| Gross margin | 29.2% | 40.4% | 34.2% | 32.3% | 30.6% |
| Operating margin | 2.9% | 15.5% | 14.5% | 11.1% | 12.7% |
| Net margin | 5.8% | 15.6% | 14.5% | 14.1% | 12.7% |
| Free cash flow margin | -18.0% | -5.8% | 15.1% | 8.0% | 27.9% |
| Return on equity | 4.0% | 12.8% | 12.0% | 17.8% | 18.8% |
| Return on assets | 2.2% | 8.0% | 8.7% | 12.9% | - |
| Current ratio | 1.86 | 2.50 | 3.49 | 3.31 | - |
Source: XBRL data JIN MEDICAL INTERNATIONAL LTD. files with the SEC, latest filing dated Feb 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
ZJYL peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ZJYL | $20.69M | -12.0% | $1.19M | 5.8% | $666.0M |
| ISRG | $11.58B | +20.5% | $2.96B | 25.5% | $156.00B |
| EW | $6.67B | +13.4% | $1.02B | 15.3% | $59.81B |
| STE | $6.17B | +8.1% | $826.90M | 13.4% | $24.97B |
| ZBH | $8.57B | +7.0% | $767.30M | 9.0% | $20.31B |
| MAS | $7.67B | +0.9% | $926.00M | 12.1% | $16.35B |
| SNN | $6.16B | +6.1% | $625.00M | 10.1% | $12.94B |
| ALGN | $4.16B | +4.4% | $491.87M | 11.8% | $12.28B |
| AIT | $5.06B | +8.5% | $424.12M | 8.4% | $10.92B |
ZJYL FAQ
9 questionsWhat is ZJYL revenue?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) reported $20.69M of revenue for fiscal 2025 (ended Sep 30, 2025). That is down 12.0% from the year before.Is ZJYL profitable?
Yes. JIN MEDICAL INTERNATIONAL LTD. earned $1.19M in net income for fiscal 2025 (ended Sep 30, 2025), a net margin of 5.8%.How much cash and debt does ZJYL have?
JIN MEDICAL INTERNATIONAL LTD. reported $7.46M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is ZJYL revenue growing?
JIN MEDICAL INTERNATIONAL LTD.'s revenue changed -12.0% in fiscal 2025, to $20.69M.What is ZJYL gross margin?
JIN MEDICAL INTERNATIONAL LTD.'s gross profit was $6.04M on $20.69M of revenue for fiscal 2025 (ended Sep 30, 2025), a gross margin of 29.2%.What is ZJYL free cash flow?
JIN MEDICAL INTERNATIONAL LTD. generated -$3.73M of free cash flow for fiscal 2025 (ended Sep 30, 2025), which is operating cash flow of $2.90M less capital expenditures.What is ZJYL earnings per share?
Diluted earnings per share were $0.01 for fiscal 2025 (ended Sep 30, 2025), from SEC filings, restated for any stock split those filings show.When did ZJYL last report financial results?
The latest statements here come from JIN MEDICAL INTERNATIONAL LTD.'s 20-F filed on Feb 10, 2026, covering the period ended Sep 30, 2025.Where does this ZJYL financial data come from?
Quantisnow builds these statements from the structured XBRL data JIN MEDICAL INTERNATIONAL LTD. files with the SEC. It is provided for information only and is not investment advice.